Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 13/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TXK | P42681 | 4/20 | 0.31 |
| ▸ | BTK | Q06187 | 4/20 | 0.31 |
| ▸ | ITK | Q08881 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23569701 | 0.84 | JAK3 (0.39) | JAK3SMN1; SMN2TXKBTK | |
| SCHEMBL20314877 | 0.84 | JAK3 (0.39) | JAK3SMN1; SMN2TXKBTK | |
| SCHEMBL22185432 | 0.84 | JAK3 (0.39) | JAK3SMN1; SMN2TXKBTK | |
| SCHEMBL23278114 | 0.83 | CACNA1A (0.36) | JAK3GPR183KDM4E | |
| SCHEMBL24870546 | 0.82 | JAK3 (0.36) | JAK3SMN1; SMN2 | |
| SCHEMBL24870794 | 0.77 | JAK3 (0.34) | JAK3 | |
| SCHEMBL17067968 | 0.77 | SMN1; SMN2 (0.36) | SMN1; SMN2KDM4E | |
| SCHEMBL20334399 | 0.76 | GPR183 (0.54) | JAK3GPR183KDM4E | |
| SCHEMBL23366022 | 0.76 | JAK3 (0.38) | JAK3SMN1; SMN2TXKBTKITK | |
| SCHEMBL22967829 | 0.75 | JAK3 (0.36) | JAK3SMN1; SMN2TXKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558955-B1 | BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | AMGEN INC (US) | 2021-08-11 | — | — | EP | disclosed |